A major success of the Canadian IMPACT-AD study was the launch, in 2021, of the national Alzheimer's disease biomarker testing program. This medical program provides access to diagnostic biomarker testing for Alzheimer's disease as part of medical care and is accessible to all Canadians.
The testing program identifies proteins – known as biomarkers – in cerebrospinal fluid that indicate the presence of a neurodegenerative condition (see our Resources page for more information). This testing can help physicians diagnose Alzheimer’s earlier and more accurately. With new therapies on the horizon, early diagnosis also aims to better support access to therapies that only target Alzheimer's pathology.
As discussed in a recent edition of Promise magazine , the overarching goal of the IMPACT-AD study, to support and improve care for Canadians living with Alzheimer's disease and related diseases, has been realized via the national medical testing program. Read more about it here and for a snapshot, click on the video below.
Comments